Hidradenitis suppurativa (HS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051119
This document outlines details of PBS-subsidised biological medicines for patients with moderate to severe hidradenitis suppurativa (HS).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Hidradenitis suppurativa (HS) quick reference
Hidradenitis suppurativa (HS) quick reference
Table 1
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB218 form | Written Electronic S85: adalimumab bimekizumab secukinumab | No | OPA | Must be treated by a:
| Yes - immediate or delayed assessment (delayed if any free text option used) |
Grandfather PB364 form | Written Electronic S85: bimekizumab | No | OPA | Must be treated by a:
| Yes - immediate or delayed assessment (delayed if any free text option used) |
Change or
PB218 form | Written Electronic S85: adalimumab bimekizumab secukinumab | No | OPA | Must be treated by a:
| Yes |
Balance of Supply - initial | Telephone Electronic S85: adalimumab bimekizumab secukinumab | No | OPA | Must be treated by a:
| Yes |
Continuing originators PB219 form | Written Electronic S85: adalimumab bimekizumab secukinumab | No | OPA | Must be treated by a:
| Yes |
Subsequent continuing biosimilars | Streamlined S85: adalimumab | No | N/A | Must be treated by a:
| N/A |
Delayed assessment
Delayed assessment due to the free text field of prior antibiotics treatment.
Table 2: this table lists the details of what to check for the delayed assessment.
Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of the antibiotics used.